UUID:0487E2B3-C03F-43A0-ABCB-B2BDBE0FF47E TCGA-EW-A2FW-01A-PR Redacted



Name:

DOB: Gender:

MRN: Location: Physician: F

Case #: Collected:

Received: Reported:

Copy To:

1CD-0-3

carcinoma, pepillary, netraductal, NOS

Sita: breast, NOS 050.9

8503/3

6/1/11

Pathologic Interpretation:

A. SENTINEL NODE #1 COUNT

- No malignancy seen in one lymph node (0/1).
- Keratin immunostain to follow.

B. SUSPICIOUS LYMPH NODE RIGHT BREAST:

- No malignancy seen in one lymph node (0/1).
- Keratin immunostain to follow.

C. SENTINEL NODE # 2 COUNT

- No malignancy seen in one lymph node (0/1).
- Keratin immunostaln to follow.

D. SENTINEL NODE #3 COUNT

- No malignancy seen in one lymph node (0/1).
- Keratin immunostain to follow.

E. SENTINEL NODE #4 COUNT

- No malignancy seen in one lymph node (0/1).
- Keratin immunostain to follow.

F. SENTINEL NODE # 5 COUNT

- No malignancy seen in one lymph node (0/1).
- Keratin immunostain to follow.

G. RIGHT BREAST, SHORT STITCH SUPERIOR LONG LATERAL:

- Invasive dudal carcinoma, poorly differentiated, Nottingham grade 2 (3 + 2 + 1 = 6), papillary type, 2.8 cm in greatest dimension.
- Resection margin is free of tumor; closest margin, 1.5 mm.
- Lymphovascular invasion is not identified.
- Ductal carcinoma in situ, high grade (DIN 3), with necrosis.
- Margins are free of DCIS.
- See tumor summary.

TUMOR SUMMARY:

Specimen:

- Partial breast

Procedure:

- Other (specify): Partial mastectomy

Lymph Node Sampling:

- Sentinel lymph node(s)

Specimen Integrity:

- Single intact specimen (margins can be evaluated)

Specimen Size:

- Greatest dimension: 11 cm
- \* Additional dimension: 10 x 6 cm

Specimen Laterality:

- Right

Tumor Site: Invasive Carcinoma

- Upper outer quadrant
- Lower outer quadrant

Tumor Size: Size of Largest Invasive Carcinoma

- Greatest dimension of largest focus of invasion over 0.1 cm; 2.8 cm

#### **Tumor Focality:**

- Single focus of invasive carcinoma

### Macroscopic and Microscopic Extent of tumor:

- Skin: Invasive carcinoma does not invade into the dermis or epidermis
- Skeletal muscle: No skeletal muscle present

# Ductai Carcinoma in Situ (DCIS):

- DCIS is present
  - Extensive intraductal component (EIC) negative
- Architectural Patterns: Comedo
- Nuclear Grade: Grade III (high)

#### Lobular Carcinoma in Situ

- Not identified

# Histologic Type of Invasive Carcinoma:

- Invasive papillary carcinoma

#### Histologic Grade: Nottingham Histologic Score

Glandular (Acinar)/Tubular Differentiation: Score 3: <10% of tumor area forming glandular/tubular structures
Nuclear Pleomorphism: Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate

variability in both size and shape Mitotic Count: Score 3

Overall Grade: Grade 3: score of 8

Margins:

- Margins uninvolved by invasive carcinoma
- -Distance from closest margin: 15 mm

- Margins uninvolved by DCIS

# Treatment Effect: Response to Presurgical (Neoadjuvant) therapy:

- In the Breast: No known presurgical therapy

- In the Lymph Nodes: No lymph nodes metastases and no prominent fibrous scarring in the nodes

### Lymph-Vascular Invasion: Not identified.

- Dermal Lymph-Vascular Invasion: Not identified

#### Lymph Nodes:

- Number of sentinel lymph nodes examined: 6
- Total number of lymph nodes examined (sentinel and nonsentinel): 6
- Number of lymph nodes with macrometastases (>0.2 cm): 0

Extranodal Extension: Not identified

\*Method of Evaluation of Sentinel Lymph Nodes: Hematoxylin and eosin (H&E), one level Immunohistochemistry (PENDING)

Pathologic Staging (pTNM): pT2 N0 MX

Primary Tumor: pT2: Tumor >20 mm but ≤50 mm in greatest dimension

Regional Lymph Nodes: (sn): Only sentinel node(s) evaluated

pNO: No regional lymph node metastasis identified histologically

Distant Metastasis: Not applicable

Ancillary Studies: Estrogen Receptor:

- Performed on another specimen

Progesterone Receptor:

- Performed on another specimen

Her2:

- Performed on another specimen

FISH for HER2/neu: NOT PERFORMED Microcalcifications: Not identified

Results: Immunoreactive tumor cells present (≥1%)

Results: Immunoreactive tumor cells present (≥1%)

Results: Negative (Score 0)

NOTE: Some immunolatiochemical antibodies are analyse specific reagents (ASRs) validated by our laboratory. These ASRs are clinically useful indicators that do not require FDA approval. These clones are used:

IDS=BR, PgR 636=PR, A485=HBR2, H-11=BCFR. All immunolatiochemical stains are used with formalin or molecular fixed, paraffin embedded tissue. Detection is by Envision Method. The results are read by a nathologist as positive or negative.

As the attending pathologist, I attest that I: (i) Examined the relevant preparation(s) for the specimen(s); and (ii) Rendered the diagnosis(es).

# Procedures/Addenda Addendum

Date Ordered: **Date Complete:** Date Reported:

Status: Signed Out

Addendum Diagnosis

SENTINEL NODE # 1 COUNT

- Keratin is negative by Immunohistochemistry.

B. SUSPICIOUS LYMPH NODE RIGHT BREAST:

- Keratin is negative by Immunohistochemistry.

C. SENTINEL NODE # 2 COUNT

- Keratin is negative by Immunohistochemistry.

D. SENTINEL NODE #3 COUNT

- Keratin is negative by Immunonistochemistry.

E. SENTINEL NODE #4 COUNT

- Keratin is negative by Immunohistochemistry.

F. SENTINEL NODE # 5 COUNT

- Keratin is negative by Immunohistochemistry.

**Intraoperative Consultation** 

A. Sentinel node # 1 count FS: Negative for carcinoma

B. Suspicious lymph node right breast FS: Negative for carcinoma

C. Sentinel node # 2 count

FS: Negative for carcinoma

D. Sentinel node # 3 count.

FS: Negative for carcinoma

E. Sentinel node # 4 count

FS: Negative for carcinoma

F. Sentinel node # 5 count

FS: Negative for carcinoma

### Clinical History:

Right breast cancer

### Operation Performed

Right partial mastectomy with sentinel node biopsy and axillary node dissection

# Pre Operative Diagnosis:

None provided

### Specimen(s) Received:

A: Sentinel node # 1 count

FS

B: Suspicious lymph node right breast FS

C: Sentinel node # 2 count

FS

D: Sentinel node # 3 count

FS

E: Sentinel node # 4 count

F: Sentinel node # 5 count

FS

G: Right breast, short stitch superior long lateral

# **Gross Description:**

- A. Received fresh is one lymph node measuring 0.7 cm in diameter. Specimen was evaluated during frozen section and submitted in one cassette.
- B. Received fresh is one tiny lymph node measuring 0.3 cm in greatest dimension. Submitted in toto in one cassette for frozen section.
- C. Received fresh is one lymph node measuring 1 cm in greatest dimension. Specimen was evaluated during frozen section and submitted in toto in one cassette.
- D. Received fresh is one lymph node measuring 1.2 cm in greatest dimension. Frozen section submitted in one cassette. Rest of adipose tissue measuring 1.5 x 1 x 0.5 cm, submitted in cassette 2. Both specimens submitted in toto in two cassettes.
- E. Received fresh is one lymph node, bisected, measuring 0.9 cm in greatest dimension. The specimen was evaluated during frozen section examination. Submitted in toto in one cassette.
- F. Received fresh is one lymph node, bisected, measuring 0.3 cm in greatest dimension. Frozen section submitted in one cassette. Rest of adipose tissue measuring 1 x 0.5 x 0.5 cm, submitted in cassette 2.
- G. Received in formalin is a 195 grams, right partial mastectomy specimen measuring 11 x 10 x 6 cm. The specimen was already cut opened when received. A very soft skin ellipse measuring 4.5 x 2 cm is present at the anterior surface. No nipple is present. An irregular shaped tan white fibrotic mass measuring 2.8x 2.5 x 2.5 cm, is present at the junction of upper-outer and lower-outer quadrants. The mass is approximately 0.9 cm from the anterior skin margin and 2.5 cm from the posterior deep inked margin. A separate irregular shaped tan white nodular mass is present measuring 0.3 cm in greatest dimension, and 0.3 cm from the main tumor mass. Sections are as follows:
  - Deep margin
  - 2 Tumor with skin
  - 3 Tumor with anterior lateral and anterior inferior
  - 4&5 Composite sections of tumor
  - 6 Tumor
  - 7 Tumor with small nodule
  - 8 Upper outer quadrant
  - 9 Inner outer quadrant
  - 10 Lower inner quadrant
  - 11 Additional tumor

Criteria

Diagnosis Discrepancy

Primary Tumor Site Discrepancy

HIPAA Discrepancy

Prior Malignancy History

Dual/Synchronous Righary Nated

Case is (circle): UALIFIED / DISQUAJFIED

Reviewer Initials Date Peviewed: